Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CYH33 in recurrent or persistent ovarian/fallopian tube/primary peritoneal clear cell carcinoma
CTR20220554Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risovalisib mesylate in clear cell ovarian cancer, fallopian tube clear cell adenocarcinoma, Clear Cell Primary Peritoneal Carcinoma (PPCCC), sponsored by Shanghai Institute of Materia Medica. Started Jul 2022; status: active.
02
Drugs
risovalisib mesylate
03
Conditions
clear cell ovarian cancerfallopian tube clear cell adenocarcinomaClear Cell Primary Peritoneal Carcinoma (PPCCC)
Beyond the preview
Go deeper on CTR20220554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220554.